PE20160215A1 - Metodo para generar una solucion purificada de un complejo de radionuclido emisor alfa - Google Patents

Metodo para generar una solucion purificada de un complejo de radionuclido emisor alfa

Info

Publication number
PE20160215A1
PE20160215A1 PE2015002566A PE2015002566A PE20160215A1 PE 20160215 A1 PE20160215 A1 PE 20160215A1 PE 2015002566 A PE2015002566 A PE 2015002566A PE 2015002566 A PE2015002566 A PE 2015002566A PE 20160215 A1 PE20160215 A1 PE 20160215A1
Authority
PE
Peru
Prior art keywords
solution
radionuclide
generate
purified solution
alpha emitter
Prior art date
Application number
PE2015002566A
Other languages
English (en)
Inventor
Alan Cuthbertson
Olav B Ryan
Janne Olsen Frenvik
Original Assignee
Bayer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer As filed Critical Bayer As
Publication of PE20160215A1 publication Critical patent/PE20160215A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Extraction Or Liquid Replacement (AREA)

Abstract

Un metodo para generar una solucion purificada de por lo menos un complejo de radionuclido emisor alfa. El metodo comprende poner en contacto una solucion del complejo de radionuclido emisor alfa y por lo menos un nuclido hijo que tiene por lo menos un ligante selectivo para los nuclidos hijos y subsiguientemente separar la solucion del ligante selectivo. Tambien, un metodo para separar por lo menos un radionuclido hijo de una solucion que comprende por lo menos un complejo de radionuclido emisor alfa. El metodo comprende poner en contacto la solucion que tiene por lo menos un ligante selectivo para los nuclidos hijos
PE2015002566A 2013-06-05 2014-06-05 Metodo para generar una solucion purificada de un complejo de radionuclido emisor alfa PE20160215A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1310028.4A GB201310028D0 (en) 2013-06-05 2013-06-05 Pharmaceutical preparation

Publications (1)

Publication Number Publication Date
PE20160215A1 true PE20160215A1 (es) 2016-05-22

Family

ID=48805787

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015002566A PE20160215A1 (es) 2013-06-05 2014-06-05 Metodo para generar una solucion purificada de un complejo de radionuclido emisor alfa

Country Status (36)

Country Link
US (2) US20160114063A1 (es)
EP (1) EP3003401B1 (es)
JP (1) JP6580559B2 (es)
KR (1) KR102321763B1 (es)
CN (1) CN105592863B (es)
AP (1) AP2015008894A0 (es)
AU (1) AU2014276885B2 (es)
BR (1) BR112015030298A2 (es)
CA (1) CA2914278C (es)
CL (1) CL2015003554A1 (es)
CR (1) CR20150642A (es)
CU (1) CU24535B1 (es)
DK (1) DK3003401T3 (es)
DO (1) DOP2015000294A (es)
EA (1) EA201501174A1 (es)
ES (1) ES2782624T3 (es)
GB (1) GB201310028D0 (es)
HR (1) HRP20200456T1 (es)
IL (1) IL242704B (es)
LT (1) LT3003401T (es)
MA (1) MA38650B1 (es)
MX (1) MX366028B (es)
MY (1) MY180717A (es)
NI (1) NI201500173A (es)
PE (1) PE20160215A1 (es)
PH (1) PH12015502715B1 (es)
PL (1) PL3003401T3 (es)
PT (1) PT3003401T (es)
RS (1) RS60091B1 (es)
SA (1) SA515370233B1 (es)
SG (1) SG11201509856RA (es)
SI (1) SI3003401T1 (es)
TN (1) TN2015000527A1 (es)
UA (1) UA120352C2 (es)
WO (1) WO2014195423A1 (es)
ZA (1) ZA201600027B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201600158D0 (en) * 2016-01-05 2016-02-17 Bayer As Purification method
GB201600161D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope purification method
MX2023008628A (es) 2021-01-22 2023-09-22 Bayer Ag Anticuerpos lrrc15 y conjugados de los mismos.
NO347755B1 (en) * 2021-10-21 2024-03-18 Blue Wave Therapeutics Gmbh Peptide-coupled alginate gels comprising radionuclides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
JP5863640B2 (ja) * 2009-04-29 2016-02-16 バイオ−ラッド ラボラトリーズ インコーポレーティッド 免疫複合体の精製
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201105298D0 (en) * 2011-03-29 2011-05-11 Algeta Asa Pharmaceutical preparation

Also Published As

Publication number Publication date
US20220023449A1 (en) 2022-01-27
CA2914278A1 (en) 2014-12-11
PT3003401T (pt) 2020-04-09
NZ714737A (en) 2021-02-26
KR102321763B1 (ko) 2021-11-05
CR20150642A (es) 2016-07-22
SG11201509856RA (en) 2015-12-30
PH12015502715A1 (en) 2016-03-28
ZA201600027B (en) 2018-07-25
EA201501174A1 (ru) 2016-10-31
PH12015502715B1 (en) 2016-03-28
ES2782624T3 (es) 2020-09-15
GB201310028D0 (en) 2013-07-17
JP2016521700A (ja) 2016-07-25
HRP20200456T1 (hr) 2020-06-26
AU2014276885A1 (en) 2015-12-17
MX2015016726A (es) 2016-06-28
MA38650B1 (fr) 2019-05-31
EP3003401A1 (en) 2016-04-13
CA2914278C (en) 2022-11-01
IL242704B (en) 2020-06-30
SA515370233B1 (ar) 2019-05-30
TN2015000527A1 (en) 2017-04-06
CN105592863B (zh) 2020-03-10
RS60091B1 (sr) 2020-05-29
CN105592863A (zh) 2016-05-18
DOP2015000294A (es) 2016-03-15
SI3003401T1 (sl) 2020-06-30
MX366028B (es) 2019-06-21
NI201500173A (es) 2016-01-06
DK3003401T3 (da) 2020-04-06
UA120352C2 (uk) 2019-11-25
MY180717A (en) 2020-12-07
AP2015008894A0 (en) 2015-12-31
BR112015030298A2 (pt) 2017-07-25
EP3003401B1 (en) 2020-01-15
KR20160030893A (ko) 2016-03-21
PL3003401T3 (pl) 2020-07-27
LT3003401T (lt) 2020-06-25
CU24535B1 (es) 2021-07-02
JP6580559B2 (ja) 2019-09-25
US20160114063A1 (en) 2016-04-28
CU20150174A7 (es) 2016-06-29
CL2015003554A1 (es) 2016-07-15
MA38650A1 (fr) 2018-03-30
WO2014195423A1 (en) 2014-12-11
AU2014276885B2 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
ECSP18053055A (es) Agonista triple de receptores de glucagón/glp-1/gip
DOP2015000261A (es) Compuesto peptídico como activador de los receptores del glp-1 y del gip
CL2018000302A1 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
ECSP17010156A (es) Compuestos aminopirimidinilo como inhibidores jak
NI201700167A (es) Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina
BR112017010303A2 (pt) anticorpos anti-cd47, métodos e usos
UA122767C2 (uk) Ацильований аналог глюкагону
TWD180243S (zh) 自行車載具
CL2018000799A1 (es) Método y sistema para asignar tareas a equipos mineros y/o de contrucción
CL2018000087A1 (es) Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen
AR097627A1 (es) Métodos y dispositivos para la codificación conjunta de canales múltiples
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
AR100543A1 (es) Mejora del desempeño de levantamiento de pozos
NI201500173A (es) Preparado farmacéutico
CL2016000746A1 (es) Un método para producir un l-aminoácido usando una bacteria de la familia de las enterobacteriaceae teniendo atenuada la expresión de un gen que codifica un transportador de fosfato
CL2016000984A1 (es) Sistema y método para la implementación de consultas de búsqueda multi-facetadas
CL2016000032A1 (es) Sistema de acoplamiento de un elemento auxiliar en una silla de ruedas
EA201890828A1 (ru) Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин
CO2018002409A2 (es) Solicitud de estados unidos no provisional para dispositivos, sistemas y métodos de autenticación fotoluminiscente
CL2015003268A1 (es) Aparato y métodos para estabilizar roca
CR20170555A (es) Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
CL2018001012A1 (es) Métodos y sistemas para retirar compuestos polares de una solución que contiene un metal
CR20150533A (es) Compuesto peptídico
AR092144A1 (es) Metodo para recuperar oro adsorbido sobre carbon activado y metodo para producir oro mediante dicho metodo